On March 18, 2026, the Food and Drug Administration (FDA) issued draft guidance entitled “General Considerations for the Use of New Approach Methodologies in Drug Development.” The guidance is meant to provide drug developers with a validation framework and general recommendations for using new approach methodologies (NAMs) in drug development. The use of NAMs can improve predictive toxicology in humans and reduce reliance on animal testing.
FDA defines NAMs to include a broad range of methods s...
Continue Reading
Sign up for FREE to read the full article and access 129K+ alternative investment headlines.
Alternative Investment News